Ensysce Biosciences, Inc. (ENSC)

NASDAQ: ENSC · Real-Time Price · USD
8.20
-0.62 (-7.03%)
At close: Jan 7, 2025, 4:00 PM
8.25
+0.05 (0.61%)
Pre-market: Jan 8, 2025, 8:53 AM EST
-7.03%
Market Cap 10.70M
Revenue (ttm) 4.42M
Net Income (ttm) -7.93M
Shares Out 1.30M
EPS (ttm) -18.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 41,557
Open 8.67
Previous Close 8.82
Day's Range 8.18 - 8.83
52-Week Range 2.12 - 30.90
Beta 0.55
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ENSC
Full Company Profile

Financial Performance

In 2023, Ensysce Biosciences's revenue was $2.23 million, a decrease of -11.61% compared to the previous year's $2.52 million. Losses were -$10.63 million, -57.64% less than in 2022.

Financial Statements

News

Ensysce Biosciences Issues Annual Shareholder Letter

~ FDA Breakthrough Therapy designation received for PF614-MPAR ~ ~ PF614-MPAR second clinical trial initiated ~ ~ Lead clinical candidate identified for OUD program ~ ~ PF614 Phase 3 trial poised to c...

1 hour ago - Accesswire

Ensysce Biosciences Regains Full Compliance with Nasdaq

SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for s...

16 days ago - Accesswire

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

~ Supply Chain Now Fully Secure for PF614-MPAR ~ SAN DIEGO, CA / ACCESSWIRE / December 10, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical comp...

4 weeks ago - Accesswire

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

~ $10 Million Commitment from Specialty Drug Manufacturer to Support Commercialization Efforts ~ SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "...

5 weeks ago - Accesswire

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe...

5 weeks ago - Accesswire

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

~ Landmark Overdose Protection Clinical Trial of PF614-MPAR ~ ~ Expects Early Interim Data in 1Q 2025 ~ SAN DIEGO, CA / ACCESSWIRE / November 26, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensys...

6 weeks ago - Accesswire

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Awarded $14 Million Multi-Year NIH Grant and Initiated Second Clinical Trial for Breakthrough Therapy PF614-MPAR Submitted Pivotal PF614 Phase 3 Protocol to the FDA for Review SAN DIEGO, CA / ACCESSWI...

2 months ago - Accesswire

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pai...

2 months ago - Accesswire

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~ ~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensy...

3 months ago - Accesswire

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

SAN DIEGO, CA / ACCESSWIRE / October 2, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain...

3 months ago - Accesswire

Ensysce Biosciences Receives Notice from Nasdaq

SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe p...

3 months ago - Accesswire

Ensysce Biosciences Presenting at Upcoming Meetings

~ New Data on Opioid Use Disorder Program at Society for Neuroscience Meeting ~ ~ Ensysce CEO Invited Expert Speaker at Formulation & Delivery US 2024 Meeting ~ SAN DIEGO, CA / ACCESSWIRE / September ...

3 months ago - Accesswire

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Phase 3 Study to Assess PF614 Efficacy in Treating Post-Surgical Pain SAN DIEGO, CA / ACCESSWIRE / September 19, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical...

3 months ago - Accesswire

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

~ PF614 and PF614-MPAR Highlighted at Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / September 13, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stag...

4 months ago - Accesswire

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

SAN DIEGO, CA / ACCESSWIRE / August 29, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe ...

4 months ago - Accesswire

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Next Clinical Trial of FDA Breakthrough Therapy PF614-MPAR Supported by $14 Million Federal Government Grant SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the ...

4 months ago - Accesswire

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

~ Substantial Award Follows FDA Breakthrough Therapy Designation for PF614-MPAR ~ ~ Federal Grant Funding Awarded to Date Now at $40 Million ~ SAN DIEGO, CA / ACCESSWIRE / August 27, 2024 / Ensysce Bi...

4 months ago - Accesswire

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an Update Note on Ensysce Bioscie...

4 months ago - GlobeNewsWire

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

PF614-MPAR Progressing to Phase 1b Study to Verify Both Overdose Protection and Effective Delivery of Oxycodone Opioid Use Disorder Program Advances with Selection of PF9001 as Lead Drug Candidate  PF...

5 months ago - Accesswire

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~ SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-...

5 months ago - Accesswire

Ensysce Biosciences Provides Mid-Year 2024 Update

~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~ ~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~ ~ Identified Lead Clinical Candidate for Opioid Use Disorder P...

6 months ago - Accesswire

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

~ Dr. Lynn Kirkpatrick, CEO, to Introduce Satellite Symposium on Severe Pain: A New Chapter for Safer Analgesics ~ SAN DIEGO, CA / ACCESSWIRE / July 9, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (...

6 months ago - Accesswire

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

~ Geoff Birkett, Chief Commercial Officer, Provides Insight Following EPHMRA Meeting ~ SAN DIEGO, CA / ACCESSWIRE / June 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company")...

6 months ago - Accesswire

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

~ Collaboration with Purisys Positions Ensysce to Expedite Lead OUD Candidate, PF9001, to IND Studies ~ SAN DIEGO, CA / ACCESSWIRE / June 25, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" ...

7 months ago - Accesswire

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

~ Selects Lead Candidate with Abuse Deterrence and Improved Safety Profile to Treat Opioid Use Disorder ~ SAN DIEGO, CA / ACCESSWIRE / June 6, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"...

7 months ago - Accesswire